Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908859 | 0.86 | FFAR1 (0.64) | MAOBFFAR1FFAR4NR4A2CYP4F2 | |
| SCHEMBL19088555 | 0.83 | TDP1 (0.58) | FFAR1FFAR4PTPN1 | |
| SCHEMBL18002939 | 0.82 | CYP4F2 (0.70) | MAOBFFAR1FFAR4MRGPRX4NR4A2 | |
| SCHEMBL1010424 | 0.80 | MAOB (0.64) | MAOBFFAR1FFAR4MRGPRX4NR4A2 | |
| SCHEMBL18003261 | 0.80 | CYP4F2 (0.58) | MAOBFFAR1FFAR4MRGPRX4NR4A2 | |
| SCHEMBL1008243 | 0.80 | MAOB (0.61) | MAOBMRGPRX4NR4A2PTPN2PTPN1 | |
| SCHEMBL5512060 | 0.79 | MAOB (0.63) | MAOBMRGPRX4NR4A2PTPN2PTPN1 | |
| SCHEMBL18002765 | 0.79 | MAOB (0.56) | MAOBMRGPRX4NR4A2PTPN2PTPN1 | |
| SCHEMBL1563165 | 0.78 | FFAR1 (0.55) | FFAR1FFAR4MRGPRX4NR4A2 | |
| SCHEMBL8350924 | 0.78 | CYP4F2 (0.60) | MAOBFFAR1FFAR4NR4A2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MAOB 3664/4885FFAR1 1292/4885FFAR4 1992/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | MAOB 3664/4885FFAR1 1292/4885FFAR4 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.